Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro

• Verfasst von: Krämer, Isabelle [VerfasserIn]
• Verfasst von: Engelhardt, Melanie [VerfasserIn]
• Verfasst von: Fichtner, Sabrina [VerfasserIn]
• Verfasst von: Neuber, Brigitte [VerfasserIn]
• Verfasst von: Medenhoff, Sergej [VerfasserIn]
• Verfasst von: Bertsch, Uta [VerfasserIn]
• Verfasst von: Hillengaß, Jens [VerfasserIn]
• Verfasst von: Raab, Marc-Steffen [VerfasserIn]
• Verfasst von: Hose, Dirk [VerfasserIn]
• Verfasst von: Ho, Anthony Dick [VerfasserIn]
• Verfasst von: Goldschmidt, Hartmut [VerfasserIn]
• Verfasst von: Hundemer, Michael [VerfasserIn]
• Titel: Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro
• Verf.angabe: Isabelle Krämer, Melanie Engelhardt, Sabrina Fichtner, Brigitte Neuber, Sergej Medenhoff, Uta Bertsch, Jens Hillengass, Marc-Steffen Raab, Dirk Hose, Anthony D. Ho, Hartmut Goldschmidt & Michael Hundemer
• E-Jahr: 2016
• Jahr: 31 May 2016
• Umfang: 10 S.
• Fussnoten: Gesehen am 26.05.2020
• Titel Quelle: Enthalten in: OncoImmunology
• Ort Quelle: Abingdon : Taylor & Franics, 2012
• Jahr Quelle: 2016
• Band/Heft Quelle: 5(2016,5) Artikel-Nummer e1139662, 10 seiten
• ISSN Quelle: 2162-402X
• DOI: doi:10.1080/2162402X.2016.1139662
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Antigen-specific T-cells
• Sach-SW: CD45RA
• Sach-SW: CD57
• Sach-SW: immunotherapy
• Sach-SW: lenalidomide
• Sach-SW: multiple myeloma
• K10plus-PPN: 1698801769

Abstract

Immunomodulation is an important part of lenalidomide's mode of action. We analyzed the impact of lenalidomide on T cells from patients with multiple myeloma during lenalidomide therapy in vivo and in patients with lenalidomide-refractory disease in vitro Patients enrolled in the German Speaking Myeloma Multicenter Group (GMMG) MM5 trial received a consolidation therapy with two cycles of lenalidomide after autologous stem cell transplantation (ASCT). Half of the study population continued treatment with lenalidomide maintenance therapy for 2 y, while the other patients received lenalidomide maintenance therapy until complete remission. We analyzed 58 patients with (n = 30) or without (n = 28) lenalidomide therapy and 12 patients refractory to lenalidomide with regards to their anti-myeloma-specific T-cell responses displayed by IFNγ, Granzyme B, and Perforin secretion. The immunophenotype of T-cells was investigated by flow cytometry. Significantly, more myeloma-specific T-cell responses were observed in patients during lenalidomide therapy, compared to patients without treatment. Furthermore, we found on T-cells from patients treated with lenalidomide a decreased CD45RA expression, indicating a maturated immunophenotype and a decreased expression of CD57, indicating functional T cells. An improved myeloma-specific T-cell response was observed in 6 out of 12 heavily pretreated patients (refractory to lenalidomide) after in vitro incubation with lenalidomide. Complementary to the results in vivo, lenalidomide decreased CD45RA expression on T cells in vitro.